. "From speaking to management, we think this is exactly the type of deal [Fate] was looking for," wrote Cantor Fitzgerald analyst Alethia Young, referring to a back-loaded agreement that gives the company the chance to keep some rights to the programs in the alliance. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies. Get the free daily newsletter read by industry experts. [Updated: 2/10/2021] Can The FATE Stock Rally Continue? [Updated: 2/10/2021] Can The FATE Stock Rally Continue? These companies have yet to prove off-the-shelf approaches can match, or surpass, what has been seen with CAR-T without triggering serious or potentially deadly immune reactions. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). Topics covered: startup launches, funding, IPOs and much more. Following the completion of the transaction, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Breaking News: FATE latest news. - The Fly See our analysis on Fate Therapeutics Stock Chances of Rise for more details. [1] [2] As of 2011, some sixty Israeli companies are listed on the Nasdaq. The decline is driven in part by the broader sell-off in high growth stocks. Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. (NYSE:BLDR), Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. (NYSE:GMS), Alphabet Inc. (NASDAQ:GOOG) Shares Bought by Capital Square LLC, Jeereddi Investments LP Increases Position in Alphabet Inc. (NASDAQ:GOOG), Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products (NYSE:SON), Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. (NYSE:GGG), MML Investors Services LLC Buys 3,360 Shares of Wolfspeed, Inc. (NYSE:WOLF), Boothbay Fund Management LLC Takes Position in Loews Co. (NYSE:L), Boothbay Fund Management LLC Sells 9,611 Shares of Portillos Inc. (NASDAQ:PTLO), MML Investors Services LLC Sells 139 Shares of Extra Space Storage Inc. (NYSE:EXR), Lazard Asset Management LLC Has $308,000 Stake in Marqeta, Inc. (NASDAQ:MQ), Lazard Asset Management LLC Has $329,000 Position in The Williams Companies, Inc. (NYSE:WMB), Boothbay Fund Management LLC Invests $267,000 in Synaptics Incorporated (NASDAQ:SYNA), 7,728 Shares in SEI Investments (NASDAQ:SEIC) Acquired by Ergoteles LLC, Lazard Asset Management LLC Trims Stake in iQIYI, Inc. (NASDAQ:IQ), 2,549 Shares in Hess Co. (NYSE:HES) Acquired by Boothbay Fund Management LLC, The Interpublic Group of Companies, Inc. (NYSE:IPG) Shares Sold by Lazard Asset Management LLC, Boothbay Fund Management LLC Acquires 38,651 Shares of Consolidated Communications Holdings, Inc. (NASDAQ:CNSL), Boothbay Fund Management LLC Takes $260,000 Position in Advanced Drainage Systems, Inc. (NYSE:WMS), Boothbay Fund Management LLC Takes $288,000 Position in ShotSpotter, Inc. (NASDAQ:SSTI). A change of 9.3% or more over five trading days (one week) is a 18% likelihood event, which has occurred 352 times out of 1945 in the last 8 years, Of these 352 instances, the stock has seen a positive movement over the next five trading days on 174 occasions, A change of 7% or more over ten trading days is a 31% likelihood event, which has occurred 597 times out of 1945 in the last 8 years, Of these 597 instances, the stock has seen a positive movement over the next ten trading days on 266 occasions, A change of 3.6% or more over twenty-one trading days is a 43% likelihood event, which has occurred 831 times out of 1944 in the last 8 years, Of these 831 instances, the stock has seen a positive movement over the next twenty-one trading days on 464 occasions, A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. sharewise - Stocks and the Wisdom of the crowd. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? Fate Therapeutics, Inc. has a 1 year low of $4.02 and a 1 year high of $43.12. Press Releases. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. Funding. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Currency in USD Follow 2W 10W 9M 6.11 +0.02 (+0.33%) At close: 04:00PM EST 6.29 +0.18 (+2.95%) After hours: 05:58PM EST. Why Is Fate Therapeutics (FATE). [Updated: 1/20/2021] Is FATE Stock Overbought? Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. Fate Therapeutics Stock Falls on Trial Data for Lymphoma - TheStreet Fate TherapeuticsiPSCAR-TCAR-NK | ONO How were Fate Therapeutics' earnings last quarter? Fate Therapeutics - Funding, Financials, Valuation & Investors Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Our daily ratings and market update email newsletter. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical companys stock valued at $367,000 after buying an additional 1,938 shares during the period. 40% of employees would recommend working at Fate Therapeutics to a friend and 22% have a positive outlook for the business. The stock has a market capitalization of $599.76 million, a P/E ratio of -2.10 and a beta of 1.53. CI Investments Inc. now owns 3,082 shares of the biopharmaceutical companys stock valued at $31,000 after purchasing an additional 2,482 shares in the last quarter. For more information, call Reed Kathrein at 844-916-0895 or email FATE@hbsslaw.com. This suggests a possible upside of 304.1% from the stock's current price. Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. Should I buy Axsome Therapeutics (AXSM) - Zacks The stock was purchased at an average cost of $5.67 per share, for a total transaction of $499,232.16. It's an emerging field of research that's still in its early stages. The shares were bought at an average price of $5.67 per share, with a total value of $499,232.16. Truist Financial reiterated a hold rating and issued a $7.00 target price (down from $46.00) on shares of Fate Therapeutics in a research note on Friday, January 6th. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. On average, they anticipate the company's stock price to reach $24.69 in the next year. The J&J partnership does give Fate some breathing room. With the shares down 60% following Fate's announced pipeline prioritization and Janssen termination, the "damage has largely been done and there is an opportunity for value-based, longer-term investors to step in," Nochomovitz tells investors in a research note. Former Qualcomm CEO Steven Mollenkopf, who retired in June 2021, pulled in total compensation of $69 million last year, which ranked highest among CEOs of the region's 100 publicly traded companies. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. Glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates. Segall Bryant & Hamill LLC Acquires 3,038 Shares of Fate Therapeutics The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. Israel had more companies listed in 2012 on the NASDAQ stock exchange than any country outside the United States, save China. The biopharmaceutical company earned $44.36 million during the quarter, compared to analyst estimates of $18.41 million. Fate is working toward a class of treatment that is based on NK cells. U.S. regulators rejected Elon Musks bid to test brain chips in humans, Cell and Gene Therapy Manufacturing: Current and Future States, Proven Tips for Converting Sites to Single IRB, GSKs RSV vaccine wins FDA panel backing, matching Pfizer, FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs. You may opt-out by. Giu 11, 2022 | narcissistic withdrawal. Lazard Asset Management LLC Raises Stake in CDW Co. (NASDAQ:CDW), Verition Fund Management LLC Raises Stock Position in Teradyne, Inc. (NASDAQ:TER), Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE). PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical companys stock worth $260,000 after buying an additional 986 shares during the last quarter. Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST The 9% rise can primarily be attributed to the announcement of positive interim data from a phase one study for patients with relapsed or refractory B-cell lymphoma. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. FT819. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. Their stock opened with $6.00 in its Oct 4, 2013 IPO. Guggenheim cut shares of Fate Therapeutics from a buy rating to a neutral rating in a research note on Tuesday, January 3rd. Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Lazard Asset I, Fate Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.75) Per Share (NASDAQ:FATE), Q1 2023 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Reduced by Analyst, Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript, Fate Therapeutics Full Year 2022 Earnings: Beats Expectations. Scott Wolchko, president and chief executive officer of Fate Therapeutics, touted the partnership with Janssen. Fate Therapeutics has a P/B Ratio of 0.86. The disclosure for this sale can be found here. Published: Apr 03, 2020 Also, Director John Mendlein purchased 88,048 shares of the businesss stock in a transaction on Wednesday, January 11th. Why Fate Therapeutics Stock Is Sliding Today | Nasdaq We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, February, 28th. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). And the recent stock price growth means that some of the positives are already priced in at the current price of $114. Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Lazard Asset Management LLC Benzinga 4 days ago FATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate. Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. The shares were sold at an average price of $5.24, for a total transaction of $240,552.68. Fate Therapeutics Announces Changes to its Board of Finally, Great West Life Assurance Co. Can bought a new stake in. While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. By Alex Keown. Will Boston Scientific Stock See Higher Levels? Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. All rights reserved. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? Could 0DTE Options Be The Cause Of The Next Market Meltdown. Fate Therapeutics Inc Stock - FATE Share Price Today, News and Discussion Fate Therapeutics has received a consensus rating of Hold. It didn't provide specific details. What other stocks do shareholders of Fate Therapeutics own? Patents Assigned to FATE THERAPEUTICS, INC. - Justia Citi analyst Yigal Nochomovitz lowered the firm's price target on Fate Therapeutics to $9 from $80 and keeps a Buy rating on the shares. Fate Therapeutics has an overall rating of 2.9 out of 5, based on over 76 reviews left anonymously by employees. Es wurde ein Verlust je Aktie von 0 . While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. Lazard Asset Management LLC lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 27.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Large investors have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC's holdings in Fate Therapeutics [] FATE stock fares better after Case 1, with an average return of 6% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 3.8% for Case 2. Now that FATE stock has seen a rise of 9% in five trading days, can it continue its upward trajectory, or is a decline imminent? How many employees does Fate Therapeutics have? Here's Why Fate Therapeutics Rose as Much as 18% Today The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.28. In the last 90 days, insiders have sold 75,708 shares of company stock valued at $396,710. FATE stock is also up a massive 18x from levels of $6 seen in early 2018, three years ago. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Today it has 9 INDs, more than 250. Shares have lost about 21% in that time frame, underperforming the S&P 500. Fate Therapeutics ( FATE) - Get Free Report stock tumbled Friday after the biopharma reported mixed results from a clinical trial of its treatment for B-cell lymphoma. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. 17.34% of the stock is owned by insiders. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the stock. It appears so. C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Dulac Edward J Iii: officer: Chief Financial Officer: FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Yuan Xu: director: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080: Robert S . Fate Therapeutics, Inc. (FATE) NasdaqGM - NasdaqGM Real Time Price. Fate turns cells from donors into induced pluripotent stem cells, which in turn can be re-engineered into a variety of different cells. March 1, 2023|markets.businessinsider.com, February 27, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com, February 13, 2023|markets.businessinsider.com. When that time comes, Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. Fate Therapeutics zog Bilanz zum jngsten Jahresviertel [4] Through the years, many have been acquired . By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, President, Chief Executive Officer & Director, Chief Financial Officer & Accounting Officer, Senior Vice President-Technical Operations. Fate Therapeutics (NASDAQ:FATE) Price Target Lowered to $7.00 at Piper Sandler, Fate Therapeutics (NASDAQ:FATE) Receives "Buy" Rating from EF Hutton Acquisition Co. Zoom Video Communications, Inc. (NASDAQ:ZM) Shares Acquired by BlackRock Inc. BlackRock Inc. Lowers Position in APA Co. (NASDAQ:APA), Piper Sandler Boosts Duolingo (NYSE:DUOL) Price Target to $127.00, BlackRock Inc. Cuts Holdings in NortonLifeLock Inc. (NASDAQ:NLOK), Altair Engineering Inc. (NASDAQ:ALTR) Insider Sells $161,325.00 in Stock, Caisse DE Depot ET Placement DU Quebec Has $2.15 Million Position in Franklin Resources, Inc. (NYSE:BEN), Capital Fund Management S.A. Makes New Investment in CVR Energy, Inc. (NYSE:CVI), 12,000 Shares in Stratasys Ltd. (NASDAQ:SSYS) Purchased by Gabelli Funds LLC. Janssen will also cover the funding costs of the R&D of the collaboration candidates. In other news, CFO Edward J. Dulac III sold 7,331 shares of the businesss stock in a transaction that occurred on Tuesday, January 10th. The data from the trials showed that eight of eleven patients being evaluated for assessment of safety and efficacy of the FT516 treatment achieved an objective response, while six of those patients achieved a complete response. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers . Shares of FATE opened at $6.01 on Tuesday. The company is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece,a roughly 47% premium to Fate's $21.07 closing price on Thursday. In-depth profiles and analysis for 20,000 public companies. FATE Fate Therapeutics Inc 6,209 $6.11 $0.02 (0.33%) Today Market Cap $583.99M Volume (M) 1.52M 52-Wk High $43.12 52-Wk Low $4.02 About Feed Sentiment Fundamentals News There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Sentiment Score Message Volume Score Disclaimer: This is informational only. Fate Therapeutics - FATE Stock Forecast, Price & News - MarketBeat Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Overall, according to data and Trefis machine learning engines calculations, patience absolutely pays for most stocks! ExodusPoint Capital Management LP Acquires Shares of 25,474 Fate That said, the treatment is still in the very early stages of clinical trials, implying there is still some time before the drug can even move to late stage trials, let alone file for approval subject to a positive outcome of the upcoming studies. Separately, Fate Therapeutics Chief Scientific Officer - Daniel Shoemaker - will be leaving the company in June this year, and this development has likely hurt the stock. Citigroup Increases Fate Therapeutics (NASDAQ:FATE) Price Target to $10 There are currently 2 sell ratings, 14 hold ratings and 6 buy ratings for the stock. According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 304.1% from its current price of $6.11. The decline is driven in part by the broader sell-off in high growth stocks. Fate Therapeutics Inc. buy EF Hutton Acquisition Co. I Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. A class action has already been filed. Now, is FATE stock poised to gain further? Several other research firms have also recently issued reports on FATE. Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. This company's $6.7 billion market cap at the moment assumes a great deal of success down the road. Identify stocks that meet your criteria using seven unique stock screeners. It is engaged in the development of programmed cellular immunotherapies for cancer and immune. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. All rights reserved. Stifel Nicolaus cut shares of Fate Therapeutics from a buy rating to a hold rating in a research note on Friday, January 6th. In fact, the average price estimate for FATE stock is $112, reflecting a large 40% premium to the current market price of $79. Fate Therapeutics: Strong Early Stage Data - SeekingAlpha Gilead to Acquire Forty Seven for $4.9 Billion - Gilead Sciences
City Of London Cemetery Find A Grave,
What To Write On Your Letting Go'' Plate,
Norma Brass For Sale,
Articles F